

Cambridge University Press

978-0-521-76223-6 - Medically Unexplained Symptoms, Somatisation and Bodily

Distress: Developing Better Clinical Services

Edited by Francis Creed, Peter Henningsen and Per Fink

Index

[More information](#)

Index

- abridged somatisation disorder, 5, 7
 - abridged somatisation SSI-4/6, 7
 - aetiological factors, 15
 - correlates of functional somatic syndromes, 17
 - correlates of medically unexplained symptoms and somatoform disorders, 15, 16
 - predictors of functional somatic syndromes, 18
 - predictors of medically unexplained symptoms and somatoform disorders, 16, 17
 - allodynia of fibromyalgia, 14
 - amitriptyline, 203
 - antidepressants, 76, 87, 203, 205
 - efficacy, 77
 - for body dysmorphic disorder, 206
 - for fibromyalgia, 84, 85
 - for functional somatic syndromes, 79, 206, 207
 - for health anxiety, 206
 - for IBS, 81
 - psychological treatment, 81
 - systematic review, 76
 - anxiety, 17, 18, 20, 78
 - anxiety comorbidity, 59
 - assessment
 - aims of, 175
 - and impacts of diagnostic label, 183, 184
 - at Research Clinic for Functional Disorders and Psychosomatics, Denmark, 183, 184
 - by a specialist mental health professional, 180, 181, 182
 - categorised as complicated or uncomplicated, 178
 - disease management approach, 176, 177
 - high risk level, 177
 - identification of patient
 - with bodily distress, 176
 - in primary/secondary care setting, 178, 179
 - intermediate risk level, 177
 - interpretation and
 - communication of tests, 184–6
 - low risk level, 177
 - mental health examination, 182
 - of MUS, dimensions and instruments, 180
 - role in patient motivation, 178
 - asthma, 81
 - back pain, 14, 76, 77, 81, 85, 137, 139, 147, 193, 205
 - barriers, to improved treatment.
 - See also* models of care
 - context of care, 124–6
 - doctor's role, 127, 128
 - dualistic context of medical care providers, 126–9
 - patient's role, 127
 - problems in policies and planning, 125, 126
 - problems with terminology, 124, 125
 - strategies for overcoming, 129
 - therapeutic relationship, 128
- Barsky's somatosensory amplification model, 50, 196
- Belgium, models of care
 - expert centres for CFS, 109, 110
 - GET and CBT, 109, 110
 - local initiatives, 109, 110
 - psychiatric day clinics, 110
 - psychosomatic clinic, 109
 - stepped care programme, 110
 - unmet needs, 109
- biofeedback, 77, 169, 170
- bodily distress disorder (BDD), 45
- bodily distress syndromes (BDS), 54, 61, 64, 97, 207, 208
 - causes of, 208
 - diagnosis of, 208
 - diagnostic criteria, 55, 56
 - functional somatic syndromes, 56
 - psychiatric and non-psychiatric syndromes, 57
 - psychobehavioural
 - characteristics, 58
 - somatic symptoms, 56
 - symptom clusters, 55
 - symptom profiles, 56
 - treatment, 208
- body dysmorphic disorder, 6
- Brief Pain Inventory, 85
- Briquet's syndrome, 48
- British Society of Gastroenterology
 - guidelines, 83
- Brown's model of rogue perception of symptoms, 51
- catastrophising beliefs, 50, 51
- central pharmacotherapy, 87
- children and adolescents,
 - MUS management in assessment, 166–8
 - beliefs and behaviours of health professionals, 165
- biofeedback, 170
- cognitive behavioural therapy, 169, 170
- coping mechanism, 161
- definitions and diagnostic categories, 159–61
- dynamic psychotherapy and systemic psychotherapies, 171
- epidemiology, 162
- family factors, 162, 163, 164
- genetics and biological factors, 164

254	Index
	<p>children and adolescents, MUS management in (<i>cont.</i>) interpersonal therapy (IPT), 170 psychiatric comorbidity, 165 psychosocial interventions, 168–71 relaxation therapy, 170 solution-focused approach, 171 therapeutic relationship, 171 treatment models, 168 chronic fatigue syndrome (CFS), 6, 10, 12, 17, 20, 47, 56, 78 accompanying psychiatric disorder, 21, 22 as main presenting feature, 13 CBT and GET, 80 definition of recovery, 80 description of services, 250 forms of, 21 healthcare costs, 27, 28 impairments, 21 in elderly, 139 outcome, 14 PACE trial, 81 prevalence, 13 relaxation therapy vs CBT, 80 risk factor, 17 services in Belgium, 109, 110 universality, 144, 145 chronic widespread pain, 12, 17 classification and pathopsychophysiology, 62, 63 bodily distress syndrome (BDS), 54 complex somatic symptom disorder (CSSD), 53, 54 conceptual issues, 60–4 DSM-IV and ICD-10, 46 functional somatic syndrome (FSS), 47 history, 48, 49 in terms of dysfunctional CNS processes, 63, 64 inconsistencies, 47 nosology and, 60, 61 positive description of cognitions and behaviour, 49–53 preliminary of medically unexplained symptoms, 53 problems, 46 psychobehavioural features, 49 somatoform disorder, 46 Clinical Interview Schedule (CIS), 145 clinical management activation treatments, 193, 194 aims of, 186 case examples, 188, 189, 190 complicated/uncomplicated functional somatic syndromes, 190, 191 positive explanation to patients, 192, 193 stepped care approach, 186–8 cognitive behaviour therapy (CBT), 73, 75, 78, 79, 187, 193, 195, 206 additional tools, 197 changing of functional beliefs and cognitions, 196 cost-effectiveness of, 85, 86, 87 efficacy of, 77 for children with MUS, 169, 170 for hypochondriasis, 199–201 functional somatic syndromes, 75, 76 getting started, 195, 196 in primary care, 83 increasing physical activity, 197 modifying selective attention, 196 multicomponent, 78 relaxation and stress reduction, 196 services in Belgium, 109 STreSS approach, 198, 199 symptom analysis, 196 systematic review, 76, 77, 80, 81 comorbid mood disorders, 79 complex somatic symptom disorder (CSSD), 45, 53, 54, 58, 61, 64, 125 diagnostic criteria, 55 Composite International Diagnostic Interview (CIDI), 7, 10, 49 conversion disorder, 5, 6 coronary artery disease, 77 Craig's description of pain, 63 Crohn's disease, 77 culture-bound syndromes, 142, 143 cyclobenzaprine, 203 Declaration of the European Parliament (P6_TA(2009)0014), 14 depression, 17, 18, 20, 59, 85 depressive disorder, 57 dhat syndrome, 143 Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV), 46, 47 Diagnostic Interview Schedule (DIS), 49 diagnostic literalism, 61 disability benefits, 30 doctor visits, reason for frequent, 3, 4 duloxetine, 84, 85, 203, 205, 206 dynamic psychotherapy, 82 dysthymia, 18 emphysema, 77 evidence-based treatment American trial of patients with somatisation, 73 chronic fatigue syndrome (CFS), 80, 81 Dutch trial, 73 effectiveness and cost-effectiveness trials in FSS, 85, 86 fibromyalgia, 84, 85 functional somatic syndromes, 75–80 healthcare costs, 71 in different settings, 69, 70 irritable bowel syndrome (IBS), 74, 81–4 Kroenke's review, 70, 71, 75 MUST trial, 72 overview, 70, 71 reassurance for patients, 74, 75 reattribution model, 72, 73 Sri Lankan trial, 73, 74 studies of CBT, 73, 75 systematic reviews, 71 TERM model, 72</p>

	Index	255
exercise therapy, 78, 79, 84, 85 for fibromyalgia, 85	prevalence in primary and secondary care, 12, 13 psychological and exercise- based treatments, 78 relationship with somatisation, 14, 15 stepped care model, 86–8 terminology, 46	services in Belgium, 109 guided self-instruction, 87
factitious illness, 160	gender differences	health anxiety, 17, 18, 51, 101, 106 CBT for, 199, 200, 201
fibromyalgia, 10, 13, 56, 78, 124, 159, 177, 178 allodynia of, 14 and cancer, 14 antidepressants for, 84, 85, 206 concurrent psychiatric disorders, 14 definition, 14 evidence based treatment, 84, 85 exercise therapy, 85 healthcare costs, 25, 26 impairments, 21 major depressive disorder, 85 outcome, 14 prevalence, 13, 14 psychological treatment and exercise, 84 subgroups, 22	body image, 134 coping behaviour, 134, 135 emotions, 134, 135 epidemiology of somatic disorders, 132, 133 gendered roles, 134, 135 genetics, 136 healthcare use, 133 health-related cognitions, 135 health-related quality of life, 135 illness attributions, 134 illness consequences, 135 in diagnostic and treatment actions, 137 patient–doctor communication, 136 personality, 134, 135 physiology, 136 psychosocial distress and psychiatric morbidity, 135 stigma and legitimacy, 137 stress and trauma, 135 symptom attribution, 134 symptom perception and symptom processing, 133 treatment response, 137 victims of sexual abuse, 135	healthcare costs, 23 associated with MUS, 22, 23 chronic fatigue syndrome, 27 evidence based treatment, 71 fibromyalgia, 25, 26 irritable bowel syndrome, 26, 27 primary care, 24 secondary care, 24, 25 somatoform disorders, 24 healthcare delivery, in European countries, 150 Hospital Anxiety and Depression Scale (HADS), 176, 205 hyperventilation syndrome, 56 hypnotherapy, 82, 83, 86 hypochondriasis, 5, 7, 10, 51, 76, 101, 106, 195 CBT for, 199, 200, 201 hysteria, 159 'hwa-byung' syndrome, 143
Fibromyalgia Impact Questionnaire, 85	general medicine – psychiatry interface disorders, 61	idiopathic symptom, 53 inpatient care, 100 interface disorders, 61 internalising disorders, 61 International Classification of Diseases (ICD), 3, 6 International Classification of Diseases of the World Health Organisation (ICD-10), 46, 47, 159 International Classification of Primary Care (the ICPC-2), 53 interpersonal psychotherapy, 88 irritable bowel syndrome (IBS), 10–12, 13, 17, 47, 124, 125, 148, 178 antidepressants for, 206 British Society of Gastroenterology, 83 concurrent psychiatric disorders, 14 cost-effectiveness of treatment, 85, 86 effectiveness of treatment, 86
fluoxetine, 203	German psychosomatic model of care, 111, 119 departments, 111 for bodily distress syndromes, 111, 112, 117 management of medically unexplained symptoms, 113 out-patient treatment, 112 psychosomatic medicine, 112, 117 traditions, 111 graded exercise therapy (GET), 79, 80, 87, 194	
functional dyspepsia, 13, 17		
functional gastro-intestinal disorders, 13		
functional somatic syndromes (FSS), 10, 47, 61 aetiological factors, 17, 18 antidepressant therapy, 76, 79 associated with physical illness, 17 classification, 47 cognitive behaviour therapy, 75 efficacy of antidepressants and CBT, 77 evidence based treatment, 75 grouping of, 48 impairment accompanying somatisation, 22 impairments in, 21 multiple somatic symptoms, 14 outcome of, 14 perpetuating factors, 18 persistent, 18 prevalence in population- based studies, 13		

256	Index	
irritable bowel syndrome (IBS) (<i>cont.</i>) evidence based treatment, 74, 81, 82 extra-gastrointestinal symptoms, 15 extra-intestinal symptoms, 99 health status associated with primary and secondary care, 22 healthcare costs, 26, 27 impairments, 21 NICE review, 82, 83 organic gastrointestinal disease, 14 outcome, 14 population-based studies, 14 post-infectious, 17 Rome criteria, 47, 125 secondary care, 99 subgroups, 22 unmet needs, 99	in single ethnic group, 147, 148 in UK hospitals, 2 management in elderly, 141, 142 mental component score (MCS), 20 outcome of, 4, 5 predictors of persistence, 16, 17 preliminary classification of, 53 prevalence in primary care, 3, 4 prevalence in secondary care, 1, 3, 5 problems with terminology, 124 proportion attending primary care, 3 proportion attending secondary care, 2 symptom clusters, 57 terminology, 44 universality of, 143–5 unmet needs in secondary care, 101, 103 variation in GP, 3, 4 mental body scanning, 49 milnacipran, 84, 203 moclobemide, 203 models of care <i>See also</i> barriers, to improved treatment administration and affiliation, 119 associated with disability and high healthcare costs, 100, 101 Belgium, 109, 110 consultation-liaison psychiatry or psychosomatics, 106 general medicine, 107 German, 111, 112, 117 inpatient care, 100 location of specialist clinic, 118 non-specialised services, 104, 106, 107 patient-centred approaches to unmet needs, 101, 102 presuppositions and challenges, 117, 118 primary care, 98 reasons for unmet needs, 103 recommended, 117–19	secondary care, 98–100 services in Belgium, 110 specialised units for bodily distress, 108, 109 staff, 118 strategies, 119 syndrome-specific specialised clinics, 107, 108 three tiers, 104 unmet needs, 97, 101 multicomponent treatment, 207 psychological, 82 multiple chemical sensitivity (MCS), 10, 47, 108 multiple sclerosis, 54 multiple somatic symptoms, 14 myalgic encephalopathy (ME), 183 negative affectivity, 61 neurasthenia, 6, 47, 159 neuroticism, 17 NICE guidelines, 82, 83, 86 non-cardiac chest pain, 13 non-specific chest pain, 47 non-ulcer dyspepsia, 47 older adults diagnosis of bodily distress syndromes, 140 epidemiology of somatic symptoms, 138–40 general perception of health, 140, 141 management of MUS in elderly, 141 opipramol, 71, 205 optimal treatment strategies for bodily distress syndromes, 248–50 identifying unmet needs, 237–9 management of bodily distress syndromes, 239–41 systems approach in UK, 241–7 pacing, 194 pain disorder, 5, 47 panic, 18 paroxetine, 206 peripheral pharmacotherapy, 87

		Index	257
Personal Health Questionnaire (PHQ-15), 7, 19, 176, 241	primary care attenders, 147	psychodynamic-interpersonal therapy, 201–3	
Personal Health Questionnaire (PHQ-7), 176	somatoform disorders in elderly, 139, 140	psychological medical clinics, 45	
Personal Health Questionnaire (PHQ-9), 176	somatoform disorders in primary and secondary care, 6, 7, 10	psychological treatment, 82	
pervasive refusal syndrome, 160	primary care. <i>See also</i> models of care	psychosomatic disorder, 45, 46	
pirindole, 203	assessment in, 178, 179	psychosomatic medicine, 45	
Plymouth healthcare system, 241	evidence based treatment, 69, 70	psychotherapy, 87, 112	
changes in clinical practice, 244, 245	generic training, 104	reattribution training (RT), 128	
gaps in, 243	health status associated with medically unexplained symptoms, 19, 20	relaxation therapy, 77, 82	
general health services, 245	healthcare costs, 24, 27	retirement pensions, 30	
general practitioners, 244	impairments assessed with IBS, 22	Schedule(s) of Clinical Assessment in Neuropsychiatry (SCAN), 7, 49	
key messages from literature, 242	models of care, 98	scientific progressivism, 61	
mental health services, 245	non-specialised services, 104	secondary care. <i>See also</i> models of care	
optimal treatment strategies, 246	prevalence of functional somatic syndromes, 12, 13	assessment in, 178, 179	
patient involvement, 244	prevalence of medically unexplained symptoms, 3	evidence-based treatment, 70	
referral management centre, 244	prevalence of somatoform disorders, 6–8	health status associated with medically unexplained symptoms, 20	
stakeholder involvement, 243, 244	proportion attending with medically unexplained symptoms, 3	healthcare costs, 24, 25	
population-based studies	treatment of bodily distress, 104	impairments assessed with IBS, 22	
association between chronic fatigue and physical illness, 17	unmet needs, 99	models of care, 98–100	
IBS, 14	PRIME MD, 7	non-specialised services, 106	
low back pain, 14	probable somatisation, 7	prevalence of functional somatic syndromes, 12, 13	
prevalence of functional somatic syndromes, 13	psychiatry, 124	prevalence of medically unexplained symptoms, 1, 3	
prevalence of medically unexplained symptoms, 4	psychobehavioural characteristics	prevalence of somatoform disorders, 6, 7	
prevalence of somatoform disorders, 10	abnormal illness behaviour, 51, 52	proportion attending with medically unexplained symptoms, 2	
somatoform disorder, 11	avoidance of physical activity, 52	selective serotonin norephrine reuptake inhibitors (SSNRIs), 205	
postviral fatigue syndrome, 47	expectation and memory, 51	selective serotonin reuptake inhibitors (SSRI), 77, 81–4, 86, 205	
pragmatic rehabilitation programme, 194	health anxiety and health concerns, 51	serotonin–norepinephrine reuptake inhibitors (SNRI), 79, 84	
pramipexole, 203	in BDS concept, 58	Short form 36 (SF-36), 18, 19, 20–22	
pregabalin, 84, 203	interpersonal problems, 52	short-term psychodynamic psychotherapies (STPP), 77, 78	
Present State Examination (PSE), 49	overinterpretation of bodily symptoms, 50	sickness absence reasons, 29	
prevalence, 1	self-concept of being weak, 50, 51	Sjogren's syndrome, 77	
hypochondriasis, 7	self-focused attention, 49, 50		
medically unexplained symptoms, 1, 3	somatic illness beliefs, 50		
of somatoform disorder in population studies, 10	psychodynamic psychotherapy, 79, 86		
somatisation, hypochondriasis and neurasthenia among			

258	Index
<p>somatisation disorder, 64</p> <p>somatoform autonomic dysfunction, 6, 47</p> <p>somatoform disorder, 61</p> <p>abridged somatisation disorder, 5</p> <p>classification, 46, 47</p> <p>concurrent physical illnesses, 7, 10</p> <p>costs associated with, 22–5</p> <p>definition, 5</p> <p>diagnostic category, 5</p> <p>DSM-IV and ICD-10, 6</p> <p>in adolescent population, 10</p> <p>multi-, 5, 6</p> <p>not otherwise specified, 6</p> <p>outcome of, 10</p> <p>population-based studies, 11</p> <p>prevalence in primary care, 8</p> <p>terminology, 45</p> <p>undifferentiated, 5, 6</p> <p>with concurrent anxiety and depression, 20, 21</p> <p>Somatoform Symptom Index (SSI), 5</p> <p>somatosensory amplification, 49</p> <p>South Asian cultural beliefs, 142, 143</p> <p>specialised treatment</p> <p>aims of, 195</p> <p>CBT, 195–201</p> <p>psychodynamic interpersonal therapy, 201–3</p> <p>psychopharmacotherapy, 203–7</p> <p>Specialised Treatment for Severe Bodily Distress Syndromes (STreSS), 198</p>	<p>assessment, 198</p> <p>effectiveness, 199</p> <p>intervention, 198, 199</p> <p>St John's wort, 205</p> <p>stepped care-model, 87</p> <p>Symptom Checklist-90-R (SCL-90R), 27</p> <p>supratentorial symptoms, 159</p> <p>temporomandibular joint disorder, 47</p> <p>temporomandibular joint pain, 10, 14</p> <p>tension headache, 47</p> <p>terminology</p> <p>criteria to evaluate, 44–6</p> <p>functional somatic syndrome, 46</p> <p>medically unexplained symptoms, 43, 44</p> <p>problems with, 124, 125</p> <p>psychosomatic disorder, 45, 46</p> <p>somatisation, 44</p> <p>somatoform disorder, 45</p> <p>training of doctors</p> <p>collaboration with specialists, 231</p> <p>evaluating effectiveness, 221</p> <p>for PPC, 229</p> <p>medical surgical specialist, 224</p> <p>model of delivery, 221</p> <p>models, 231, 232</p> <p>of consultation-liaison psychiatrists, 226, 233</p> <p>of general non-psychiatric specialists, 222, 224</p> <p>of general practitioners, 240</p> <p>of general psychiatrists, 224, 225</p> <p>of healthcare professionals, 227</p> <p>of medical specialists, 240, 241</p> <p>of social workers, 227</p> <p>of specialists in bodily distress and functional somatic syndromes, 226</p> <p>psychosomatic basic care, 228, 229</p> <p>psychosomatic diagnosis, 229, 230</p> <p>psychosomatic medicine in Germany, 228</p> <p>reattribution model, 218, 220</p> <p>teaching of primary care physicians, 217, 218</p> <p>TERM model of teaching, 218–22, 224–27</p> <p>transcultural psychiatry, 144</p> <p>treatment seeking behaviour, across cultures, 148, 149</p> <p>in low and middle income countries, 149, 150</p> <p>tricyclic antidepressants (TCAs), 77, 79, 85, 86, 205, 206</p> <p>tropisetron, 203</p> <p>undifferentiated somatoform disorder, 5, 10, 14</p> <p>unmet needs, 97, 101, 109, 237</p> <p>patient-centred approaches, 101, 102</p> <p>primary care, 99</p> <p>reasons, 103</p> <p>validators, of clinical syndromes, 61</p> <p>venlafaxine, 71, 205</p>